Yusuke Johira

Hiroshima, 7348553, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

Journal: Microorganisms

Published: March 08, 2026

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

Journal: Internal medicine (Tokyo, Japan)

Published: September 03, 2025

Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution.

Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution.

Journal: DEN open

Published: March 05, 2025

Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease.

Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease.

Journal: Journal of pharmaceutical health care and sciences

Published: September 02, 2024

Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single-institution study.

Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single-institution study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 07, 2024

Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma.

Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 09, 2024

Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC.

Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC.

Journal: European journal of gastroenterology & hepatology

Published: February 26, 2024

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.

Journal: Cancer medicine

Published: October 14, 2023

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Journal: Cancers

Published: September 30, 2023

Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.

Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.

Journal: Yonago acta medica

Published: August 25, 2023

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.

Journal: Cancers

Published: March 27, 2023

The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.

The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.

Journal: Oncology

Published: February 05, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026